表皮生长因子受体突变早期非小细胞肺癌的亚肺叶切除
该研究分析了2010至2020年间1395例影像学实性为主、测量2至4厘米、无临床淋巴结受累的早期非小细胞肺癌患者的临床病理和手术结局,其中亚肺叶切除231例、肺叶切除1164例,并按EGFR突变状态和手术方式分组。中位随访45.3个月,EGFR突变阳性患者中亚肺叶切除(n=39)的5年总生存率为80.5%(95%CI 51.3%-93.2%),肺叶切除(n=359)为88.8%(95%CI 84.1%-92.1%),两组可比(P=.16)。结论认为,对于经过适当选择的、外周型、测量2至4厘米且携带EGFR突变的早期非小细胞肺癌患者,切缘安全的亚肺叶切除可能是可行选择,因其总生存与肺叶切除相当。
要点
- EGFR突变阳性患者中亚肺叶切除与肺叶切除的5年总生存率分别为80.5%与88.8%,差异无统计学显著(P=.16)。
- 多变量Cox回归显示手术方式在全队列中是总生存的独立预后因素(HR 0.6,95%CI 0.4-1.0,P=.028),但在EGFR突变患者中不是(HR 0.6,95%CI 0.2-1.7,P=.32)。
- 作者认为,切缘安全的亚肺叶切除对经过适当选择的、外周型、2至4厘米且EGFR突变的早期非小细胞肺癌可能是可行选择。
核心结论
- 亚肺叶切除在EGFR突变阳性、外周型、测量2至4厘米的早期非小细胞肺癌中提供与肺叶切除相当的总生存,作者认为切缘安全的亚肺叶切除对经过适当选择的此类患者可能是可行选择。
研究设计与样本
- 分析2010至2020年间1395例影像学实性为主、测量2至4厘米、无临床淋巴结受累且接受完全切除的非小细胞肺癌患者的临床病理和手术结局,按EGFR突变状态和手术方式分组。
- 患者接受亚肺叶切除(n=231)或肺叶切除(n=1164),中位随访45.3个月。
主要发现
- EGFR突变阳性患者中亚肺叶切除(n=39)的5年总生存率为80.5%(95%CI 51.3%-93.2%),肺叶切除(n=359)为88.8%(95%CI 84.1%-92.1%),两组可比(P=.16)。
- 多变量Cox回归分析显示,手术方式在全队列中是总生存的独立预后因素(HR 0.6,95%CI 0.4-1.0,P=.028)。
- 在EGFR突变肿瘤患者中,手术方式不是总生存的独立预后因素(HR 0.6,95%CI 0.2-1.7,P=.32)。
临床怎么用
- 作者认为,对于经过适当选择的、外周型、测量2至4厘米且携带EGFR突变的早期非小细胞肺癌患者,切缘安全的亚肺叶切除可能是可行选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Lobectomy is a standard surgical procedure for peripherally located early-stage non-small cell lung cancers (NSCLCs) measuring 2 to 4 cm. However, it is unclear whether sublobar resections, such as wedge resection and segmentectomy, are effective in treating tumors with driver mutations in the epidermal growth factor receptor (EGFR). METHODS: We analyzed the clinicopathologic findings and surgical outcomes of 1395 patients with radiologically solid-dominant NSCLC measuring 2 to 4 cm, without clinical lymph node involvement, who underwent complete resection between 2010 and 2020. The patients, who underwent sublobar resections (n = 231) or lobectomy (n = 1164), were categorized by their EGFR mutation status and the surgical procedures performed. The follow-up was conducted for a median of 45.3 months. RESULTS: The 5-year overall survival (OS) rates after sublobar resections (n = 39) were comparable to those after lobectomy (n = 359) in patients with EGFR mutation-positive tumors (80.5% [95% CI, 51.3%-93.2%] vs 88.8% [95% CI, 84.1%-92.1%], respectively; P = .16). Multivariable Cox regression analysis of OS revealed that the surgical procedure was an independent prognostic predictor in the entire cohort (hazard ratio, 0.6; 95% CI, 0.4-1.0; P = .028), but it was not an independent prognostic predictor in patients with EGFR-mutated tumors (hazard ratio, 0.6; 95% CI, 0.2-1.7; P = .32). CONCLUSIONS: Sublobar resection with a secure surgical margin could be a viable option for appropriately selected patients with peripheral early-stage NSCLC tumors measuring 2 to 4 cm and harboring EGFR mutations, because it provides comparable OS to that of lobectomy.
引用
- Mimae T, Miyata Y, Tsubokawa N, et al. Sublobar Resection in Early Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutant. Ann Thorac Surg. 2024. PMID: 38199462. doi:10.1016/j.athoracsur.2023.12.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。